Top

Published in:

01-12-2020 | Septicemia | Editorial

Reliability of biomarkers of sepsis during extracorporeal therapies: the clinician needs to know what is eliminated and what is not

Authors: Patrick M. Honore, Sebastien Redant, David De Bels

Published in: Critical Care | Issue 1/2020

Excerpt

The evolution of renal replacement therapy (RRT) techniques, and the increasing number of critically ill patients receiving extracorporeal therapies, has presented clinicians with a significant problem: if biomarkers are removed by RRT, can they still be considered reliable in their role of guiding diagnosis and treatment? …

Clark WR, Gao D, Lorenzin A, Ronco C. Membranes and sorbents. Contrib Nephrol. 2018;194:70–9. https://doi.org/10.1159/000485603.CrossRefPubMed

Ankawi G, Xie Y, Yang B, Xie Y, Xie P, Ronco C. What have we learned about the use of Cytosorb adsorption columns? Blood Purif. 2019;48(3):196–202. https://doi.org/10.1159/000500013.CrossRefPubMed

Yumoto M, Nishida O, Moriyama K, et al. In vitro evaluation of high mobility group box 1 protein removal with various membranes for continuous hemofiltration. Ther Apher Dial. 2011;15:385–93. https://doi.org/10.1111/j.1744-9987.2011.00971.x.CrossRefPubMed

Gao N, Yan C, Zhan G. Changes of serum procalcitonin (PCT), C-reactive protein (CRP), interleukin-17 (IL-17), interleukin-6 (IL-6), high mobility group protein-B1 (HMGB1) and D-dimer in patients with severe acute pancreatitis treated with continuous renal replacement therapy (CRRT) and its clinical significance. Med Sci Monit. 2018;24:5881–6. https://doi.org/10.12659/MSM.910099.CrossRefPubMedPubMedCentral

Level C, Chauveau P, Guisset O, et al. Mass transfer, clearance and plasma concentration of procalcitonin during continuous veno-venous hemofiltration in patients with septic shock and acute oliguric renal failure. Crit Care. 2003;6:R160–6. https://doi.org/10.1186/cc2372.CrossRef

Wahl HG, Graf S, Renz H, Fassbinder W. Elimination of the cardiac natriuretic peptides B-type natriuretic peptide (BNP) and N-terminal proBNP by hemodialysis. Clin Chem. 2004;50:1071–4. https://doi.org/10.1373/clinchem.2003.030692.CrossRefPubMed

Mueller T, Gegenhuber A, Kronabethleitner G, Leitner I, Haltmayer M, Dieplinger B. Plasma concentrations of novel cardiac biomarkers before and after hemodialysis session. Clin Biochem. 2015;48:1163–6. https://doi.org/10.1016/j.clinbiochem.2015.07.031.CrossRefPubMed

Fujii E, Fujino K, Eguchi Y. An evaluation of clinical inflammatory and coagulation markers in patients with sepsis: a pilot study. Acute Med Surg. 2019;6(2):158–64. https://doi.org/10.1002/ams2.397.CrossRefPubMedPubMedCentral

De Freitas CN, Gaudet A, Portier L, et al. Endocan, sepsis, pneumonia, and acute respiratory distress syndrome. Crit Care. 2018;22:280. https://doi.org/10.1186/s13054-018-2222-7.CrossRef

10.

Hureau M, Gaudet A, De Freitas CN, et al. Endocan is a reliable biomarker during continuous renal replacement therapy. Crit Care. 2019;23(1):296. https://doi.org/10.1186/s13054-019-2585-4.CrossRefPubMedPubMedCentral

11.

Ketter P, Yu J-J, Cap AP, et al. Pentraxin 3: an immune modulator of infection and useful marker for disease severity assessment in sepsis. Exp Rev Clin Immun. 2016;12(5):501–7. https://doi.org/10.1586/1744666X.2016.1166957.CrossRef

12.

Schilder L, Nurmohamed SA, ter Wee PM, et al. Putative novel mediators of acute kidney injury in critically ill patients: handling by continuous venovenous hemofiltration and effect of anticoagulation modalities. BMC Nephrol. 2015;16:178. https://doi.org/10.1186/s12882-015-0167-5.CrossRefPubMedPubMedCentral

13.

Fisher J, Linder A. Heparin-binding protein: a lay player in the pathophysiology of organ dysfunction in sepsis. J Intern Med. 2017;281:562–74. https://doi.org/10.1111/joim.12604.CrossRefPubMed

14.

Samuelsson L, Tydén J, Herwald H, et al. Plasma levels of heparin binding protein (HBP) after the start of CRRT. PLoS One. 2019 Aug 29;14(8):e0221813. https://doi.org/10.1371/journal.pone.0221813.CrossRefPubMedPubMedCentral

15.

Roderburg C, Benz F, Vargas Cardenas D, et al. Persistently elevated osteopontin serum levels predict mortality in critically ill patients. Crit Care. 2015;19:271. https://doi.org/10.1186/s13054-015-0988-4.CrossRefPubMedPubMedCentral

Title: Reliability of biomarkers of sepsis during extracorporeal therapies: the clinician needs to know what is eliminated and what is not
Authors: Patrick M. Honore
Sebastien Redant
David De Bels
Publication date: 01-12-2020
Publisher: BioMed Central
Keywords: Septicemia
Septicemia
Heparin
Biomarkers
Published in: Critical Care / Issue 1/2020
Electronic ISSN: 1364-8535
DOI: https://doi.org/10.1186/s13054-020-03277-8

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Reliability of biomarkers of sepsis during extracorporeal therapies: the clinician needs to know what is eliminated and what is not

Excerpt

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2020

Adjuvant corticosteroid therapy for critically ill patients with COVID-19

Spontaneous hemothorax in 4 COVID-19 ARDS patients on VV-ECMO revealing pulmonary artery aneurysms

Delayed persistence of elevated monocytic MDSC associates with deleterious outcomes in septic shock: a retrospective cohort study

Plasma levels of soluble ACE2are associated with sex, Metabolic Syndrome, and its biomarkers in a large cohort, pointing to a possible mechanism for increased severity in COVID-19

The interaction between arterial oxygenation and carbon dioxide and hospital mortality following out of hospital cardiac arrest: a cohort study—do not dismiss confounders!

Procedural volume and outcomes in patients undergoing VA-ECMO support